CRELD2, Human (329a.a, HEK293, His)

AKKPTPCHRCRGLVDKFNQGMVDTAKKNFGGGNTAWEEKTLSKYESSEIRLLEILEGLCESSDFECNQMLEAQEEHLEAWWLQLKSEYPDLFEWFCVKTLKVCCSPGTYGPDCLACQGGSQRPCSGNGHCSGDGSRQGDGSCRCHMGYQGPLCTDCMDGYFSSLRNETHSICTACDESCKTCSGLTNRDCGECEVGWVLDEGACVDVDECAAEPPPCSAAQFCKNANGSYTCEECDSSCVGCTGEGPGNCKECISGYAREHGQCADVDECSLAEKTCVRKNENCYNTPGSYVCVCPDGFEETEDACVPPAEAEATEGESPTQLPSREDL

[1]Ortiz JA, et al. The cysteine-rich with EGF-like domains 2 (CRELD2) protein interacts with the large cytoplasmic domain of human neuronal nicotinic acetylcholine receptor alpha4 and beta2 subunits. J Neurochem. 2005 Dec;95 (6) :1585-96.|[2]Tang Q, et al. CRELD2, endoplasmic reticulum stress, and human diseases. Front Endocrinol (Lausanne) . 2023 Mar 2;14:1117414.|[3]Maslen CL, et al. CRELD2: gene mapping, alternate splicing, and comparative genomic identification of the promoter region. Gene. 2006 Nov 1;382:111-20|[4]Boyle ST, et al. ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism. Nat Cell Biol. 2020 Jul;22 (7) :882-895.|[5]Dennis EP, et al. CRELD2 Is a Novel LRP1 Chaperone That Regulates Noncanonical WNT Signaling in Skeletal Development. J Bone Miner Res. 2020 Aug;35 (8) :1452-1469.